Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.47 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5001600 | 0.93 | BACE1 (0.46) | BACE1KCNH2 | |
| SCHEMBL5002063 | 0.86 | BACE1 (0.43) | BACE1KCNH2BACE2 | |
| SCHEMBL8234379 | 0.85 | BACE1 (0.45) | BACE1KCNH2 | |
| SCHEMBL8240965 | 0.85 | CHEK2 (0.47) | BACE1KCNH2 | |
| SCHEMBL14010719 | 0.82 | BACE1 (0.47) | BACE1KCNH2BACE2 | |
| Trifluoroacetic Acid SCHEMBL5001534 | 0.82 | BACE1 (0.43) | BACE1KCNH2 | |
| SCHEMBL8240648 | 0.82 | BACE1 (0.60) | BACE1KCNH2 | |
| SCHEMBL8240666 | 0.82 | BACE1 (0.58) | BACE1KCNH2BACE2 | |
| Trifluoroacetic Acid SCHEMBL5001495 | 0.82 | BACE1 (0.44) | BACE1KCNH2 | |
| Trifluoroacetic Acid SCHEMBL5007768 | 0.81 | BACE1 (0.42) | BACE1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293709-A1 | Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293709-A1 | Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| WO-2007058583-A2 | NOVEL 2-AMINO-HETEROCYCLES USEFUL IN THE TREATMENT OF ABETA-RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293709-A1 | Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies | PSEN2, APP, PSEN1 | BACE1 4/4885KCNH2 2421/4885BACE2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.